Semaglutide sequence explained: the 31-amino acid peptide chain, key modifications, and how it compares to other GLP-1 drugs. Learn the details.
The semaglutide sequence is a 31-amino acid peptide chain that is structurally similar to human glucagon-like peptide-1 (GLP-1). It contains two key modifications: an α-aminoisobutyric acid (Aib) substitution at position 8 and a fatty acid side chain attached to lysine at position 26. These changes give semaglutide a longer half-life and resistance to enzymatic breakdown compared to natural GLP-1.
Semaglutide is the active ingredient in several FDA-approved medications for type 2 diabetes and chronic weight management. Its sequence is the foundation of its pharmacology, and understanding it helps explain why the drug works once weekly rather than requiring continuous infusion.
What Is the Semaglutide Sequence?
The semaglutide sequence is built from the same 31 amino acids as human GLP-1(7-37), with targeted substitutions. In one-letter amino acid code, the sequence is:
H-Aib-EGTFTSDVSSYLEGQAAK(AEEA-AEEA-γGlu-17-carboxyheptadecanoyl)-EFIAWLVRGRG
In three-letter code, it reads: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γGlu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
This chain folds into an alpha-helical structure that binds to the GLP-1 receptor. The sequence's length and specific residues determine how tightly it binds and how long it survives in the bloodstream.
Key Modifications in the Semaglutide Sequence
Two modifications distinguish semaglutide from native GLP-1. These changes are critical for its clinical profile.
- Aib at position 8: The natural alanine at position 8 is replaced with α-aminoisobutyric acid. This bulky, non-natural amino acid blocks the DPP-4 enzyme from cleaving the peptide, greatly extending its half-life.
- Acylated lysine at position 26: A fatty acid chain is attached to the lysine side chain via a linker (AEEA-AEEA-γGlu). This fatty acid binds to serum albumin, which protects the peptide and slows renal clearance.
The fatty acid chain is a 17-carboxyheptadecanoyl group, a C18 diacid. This modification allows semaglutide to remain active for about one week after a single injection.
Understanding the semaglutide ingredients helps clarify how the peptide is formulated for both injectable and oral products. The oral version (Rybelsus) includes an absorption enhancer called SNAC, which is not part of the peptide sequence itself.
How the Semaglutide Sequence Compares to Other Peptides
Semaglutide is often studied alongside other peptide therapeutics. The table below compares its sequence features with cagrilintide and AOD 9604.
| Peptide | Amino Acid Length | Key Sequence Features | Primary Receptor Target |
|---|---|---|---|
| Semaglutide | 31 | Aib8 substitution; acylated Lys26 with C18 fatty acid | GLP-1 receptor |
| Cagrilintide | 37 | Amylin analog; modified for long action | Amylin and calcitonin receptors |
| AOD 9604 | 15 | Fragment of human growth hormone (176-191) | Fat metabolism pathways (not GLP-1) |
Researchers often explore cagrilintide and semaglutide together because both are being investigated for obesity treatment. Clinical trials have tested combination dosages, but these are not yet approved by the FDA.
Some studies also compare aod 9604 and semaglutide, though they work through completely different mechanisms. AOD 9604 targets fat breakdown, while semaglutide reduces appetite and slows gastric emptying.
Why the Sequence Matters for Stability and Function
The semaglutide sequence is engineered for stability. Native GLP-1 has a half-life of only 1-2 minutes because DPP-4 rapidly degrades it. Semaglutide's Aib substitution prevents this degradation.
The fatty acid side chain promotes reversible binding to albumin. This creates a reservoir in the blood, allowing once-weekly dosing. Without this modification, semaglutide would be cleared too quickly to be practical.
For oral semaglutide, the sequence is the same, but the tablet includes SNAC to enhance absorption across the stomach lining. The sequence itself remains vulnerable to proteolysis in the gut, which is why the oral formulation requires careful timing and a specific carrier.
Safety and Side Effects of Semaglutide
Semaglutide is generally well-tolerated, but it can cause gastrointestinal side effects. Common semaglutide side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. These often diminish as the body adjusts.
More serious risks include pancreatitis, gallbladder disease, and diabetic retinopathy complications. The FDA has issued a boxed warning for thyroid C-cell tumors based on animal studies. However, it is important to note that human data have not confirmed a causal link to cancer. People with a history of medullary thyroid carcinoma or MEN2 should not use semaglutide.
In the semaglutide uk, it is available under brand names such as Ozempic, Wegovy, and Rybelsus, subject to prescription. Online forums like Reddit contain anecdotal reviews, but these personal stories are not a substitute for professional medical advice. Always consult a healthcare provider before starting or changing any medication.
Frequently Asked Questions
What is the exact amino acid sequence of semaglutide?
The semaglutide sequence is His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γGlu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly. It is a 31-amino acid peptide with an Aib substitution at position 8 and an acylated lysine at position 26.
How is semaglutide different from human GLP-1?
Semaglutide shares the same 31-amino acid backbone as human GLP-1 but has two key modifications. The alanine at position 8 is replaced with Aib, and a fatty acid chain is attached to lysine at position 26. These changes make semaglutide resistant to DPP-4 and give it a half-life of about one week.
Is semaglutide FDA-approved for weight loss?
Yes. The FDA has approved semaglutide under the brand name Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Ozempic and Rybelsus are approved for type 2 diabetes. All forms require a prescription and medical supervision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.